The original five-year joint EU regulatory network strategy 2021-2025 (EMANS 2025) is undergoing a revision to update it according to the last regulatory and technological innovation. The draft EMANS 2028 strategy published by EMA and the Heads of Medicines Agencies (HMA) was open to public consultation until 30 November 2024. “The six focus areas have been carefully chosen to support the network’s core work of evaluating medicines as we take strides to promote the development of medicines and ensure that they reach those who need them.”, said Maria Lamas, Chair of the HMA Management Group.
EMANS 2028’s strategic focus areas aim to facilitate pathways for access to medicines through healthcare systems in the EU. Data, digitalisation and artificial intelligence would support decision-making processes and better efficiency. The creation of a regulatory and research environment aims improving innovation and competitiveness of the EU’s healthcare sector. Potential threats have also been considered, including antimicrobial resistance, as well as an improved availability of medicines to protect public and animal health. Last but not least, the EU regulatory network should benefit from enough resources to support its scientific and regulatory decision making. The final strategy should be adopted by March 2025.